BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3618626)

  • 1. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.
    Crouse JR
    Am J Med; 1987 Aug; 83(2):243-8. PubMed ID: 3618626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia: a relative contraindication to the use of bile acid-binding resins?
    Denke MA; Grundy SM
    Hepatology; 1988; 8(4):974-5. PubMed ID: 3391527
    [No Abstract]   [Full Text] [Related]  

  • 3. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study of colestipol and colestyramine in children and adolescents with familial hypercholesterolaemia (author's transl)].
    Mordasini R; Twelsick F; Oster P; Schellenberg B; Raetzer H; Heuck CC; Schlierf G
    Monatsschr Kinderheilkd (1902); 1978 Jul; 126(7):436-40. PubMed ID: 672910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin.
    Glueck CJ; Fallat RW; Mellies M; Tsang RC
    Pediatrics; 1976 Jan; 57(1):68-74. PubMed ID: 174057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia.
    Glueck CJ; Mellies MJ; Dine M; Perry T; Laskarzewski P
    Pediatrics; 1986 Aug; 78(2):338-48. PubMed ID: 3526270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in plasma lipoproteins in subjects treated with the bile acid-sequestering resin polidexide (Secholex).
    Simons LA; Williams PF
    Aust N Z J Med; 1976 Apr; 6(2):127-30. PubMed ID: 184773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail.
    Day CE
    Artery; 1990; 17(5):281-8. PubMed ID: 2396902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels.
    LaRosa J
    Cardiology; 1989; 76 Suppl 1():55-61; discussion 61-4. PubMed ID: 2653624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss improves lipoprotein lipid profiles in patients with hypercholesterolemia.
    Davis TA; Anderson EC; Ginsburg AV; Goldberg AP
    J Lab Clin Med; 1985 Oct; 106(4):447-54. PubMed ID: 4045301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of colestipol therapy in Type II hyperlipoproteinemia.
    Lees AM; McCluskey MA; Lees RS
    Atherosclerosis; 1976; 24(1-2):129-40. PubMed ID: 182181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol.
    Clifton-Bligh P; Miller NE; Nestel PJ
    Clin Sci Mol Med; 1974 Dec; 47(6):547-57. PubMed ID: 4375013
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
    Schmidt EB; Illingworth DR; Bacon S; Mahley RW; Weisgraber KH
    Atherosclerosis; 1993 Jan; 98(2):213-7. PubMed ID: 8457260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia.
    Glueck CJ; Ford S; Scheel D; Steiner P
    JAMA; 1972 Nov; 222(6):676-81. PubMed ID: 4562098
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
    Witztum JL; Schonfeld G; Weidman SW
    J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cholestyramine in the treatment of hypercholesterolemia. Our experience in 11 cases].
    MaĆ­z A; Arteaga A; Villanueva CL; Velasco N; Acosta AM
    Rev Med Chil; 1990 Sep; 118(9):1009-13. PubMed ID: 2152729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.